Please login to the form below

Not currently logged in
Email:
Password:

BMS sales up 14 per cent

Successful launches helped second-quarter sales for Bristol-Myers Squibb sales increase 14 per cent according to the pharmaceutical firm’s financial results

Successful launches helped second-quarter sales for Bristol-Myers Squibb (BMS) sales increase 14 per cent according to the pharmaceutical firm's financial results.

US-based BMS had revenue of $5.43bn for the quarter, compared to $4.77bn for the same period in 2010. This increase in revenue was helped by the launch of skin cancer drug Yervoy (ipilimumab) and Nulojix (belatacept), an immunosupressant to be used following a kidney transplant.

The company also saw sales for Plavix (clopidogrel bisulfate) increase 15 per cent to $1.87bn to remain BMS' best-selling product. The drug, which is co-marketed by Sanofi, was granted an extra six months of marketing exclusivity by the US Food and Drug Adminisration (FDA) in January 2011.

In its financial guidance for the year, the company expects high single-digit revenue growth, as well as extra expense in marketing, sales and administration. Advertising expenses are expected to decrease.

28th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics